HNB
TCRT icon

Huntington National Bank’s Alaunos Therapeutics TCRT Stock Holding History

Huntington National Bank’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-56
Closed -$27K – 1864
2018
Q3 		$27K Hold
56
– – ﹤0.01% 1154
2018
Q2 		$25K Hold
56
– – ﹤0.01% 1162
2018
Q1 		$33K Buy
+56
New +$34.9K ﹤0.01% 1088

Other funds holding TCRT

MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MVP
Miller Value Partners Sarasota, Florida $383M AUM 38.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TS
Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Huntington National Bank's TCRT Position: Q4 2018 in Review

Huntington National Bank sold out of Alaunos Therapeutics (TCRT) in Q4 2018, closing a stake of 56 shares — an estimated $27K sold.

Huntington National Bank first reported a position in TCRT in Q1 2018 and held it in 3 quarters. The position peaked at $33K in Q1 2018. 137 funds tracked by Wall St. Rank hold TCRT as of Q4 2018.

  • Huntington National Bank reported no remaining Alaunos Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Huntington National Bank sold 56 Alaunos Therapeutics shares in Q4 2018, an estimated $27K.
  • Huntington National Bank first reported a position in Alaunos Therapeutics in Q1 2018 and held it in 3 quarters.
  • Huntington National Bank's Alaunos Therapeutics position peaked at $33K in Q1 2018.
  • 137 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q4 2018.

Based on Huntington National Bank's 13F filing for Q4 2018, filed 28 Jan 2019.